7716 Report 2009. qxd 16 6 09 16:08 Page 18 18 19 BTG plc Annual Report 2009 Chairmans statement Chairmans statement We have created the platform to build a successful specialty pharmaceuticals company.
I am delighted that the acquisition of Board changes Christine Soden, who joined BTG in July 2005 as Chief Protherics PLC, which was completed Financial Officer and became Chief Operating Officer in December 2008, received such following the acquisition of Protherics, retired from overwhelming support from both the Board on 31 March 2009 and leaves BTG in June sets of shareholders.
On behalf of the Board, I would like to thank the enlarged Group has the resources, Christine for her many contributions to the companys capabilities, scale and strategy strategic, financial and operational development.
to become a sustainably profitable We wish her well for the future.
Rolf Soderstrom, former Protherics Financial Director, joined BTG as Chief Financial Officer Progress with integrating the following the acquisition of Protherics on 4 December businesses has been rapid.
He is a strong addition to the Board and has we had made key decisions about the already played a major role in integrating the pipeline, personnel and sites and so business and getting it on track to achieve the we were ready to start the new financial planned cost savings.
year with clarity on goals, roles and We are pleased that Jim OShea joined us as responsibilities.
He brings significant industry experience from his previous roles Results for the year at Sepracor and Zeneca Pharmaceuticals that will be The reported financial results for the year show valuable as we build our US commercial operations.
strong underlying financial performance with organic growth from our recurring revenues and Outlook cash of 78.2m at the year-end.
We anticipate continued good performance in Revenues of 84.8m 07 08: 75.0m our underlying business.
Our revenues derive from included 13.4m from new lines of business acquired a broad range of products, many of which serve following the acquisition of Protherics.
Gross profit critical medical needs.
Having taken key decisions after revenue sharing and cost of sales increased on restructuring, we are on track to reduce operating by 11.2% to 47.7m 07 08: 42.9m.
Total operating expenses by 10m by the end of the 2010 11 financial expenses increased during the year as we included year.
In addition, having completed our portfolio the costs of the expanded BTG operations in the UK, review, we anticipate that research and development Australia and the United States.
Operating profit expenses will reduce as planned by 10m by 2010 11. before acquisition adjustments and reorganisation I would like to thank our management costs was 7.0m 07 08: 16.6m.
After providing for and employees, including those newly joined from the costs of reorganisation and making acquisition Protherics, who have worked very hard and shown adjustments, the operating loss for the year was professionalism and commitment as we have 9.2m 07 08: 8.5m profit.
We ended the year integrated the businesses.
I believe that we have with a loss after tax of 13.1m 07 08: 8.8m profit the team, resources and strategy to continue our delivering a loss per share of 7.1p 07 08: earnings transformation into a sustainably profitable specialty per share of 5.9p.
The acquisition of Protherics has provided BTG with the opportunity to build a profitable specialty Dr John Brown pharmaceuticals business.
We are working quickly Chairman to leverage the underpinning strength of our revenue streams and to drive the cost savings from integration.
Our strong financial position provides an excellent platform for us to grow as well as stability in the current uncertain economic climate.
7716 Report 2009. qxd 16 6 09 16:08 Page 19 We have the team, resources and strategy to continue our transformation.
